Filters

Latest News

2019-01-10 07:49:44

R&D biopharmaceutical industry embraces NEW Code of Practice to boost business integrity worldwide

The new Code of Practice in place from 1 January 2019, imposes a complete ban on gifts and promotional aids ...

Read More

2018-12-10 13:14:17

Unjela Kaleem joins global pharma association as Director of Communications

Geneva, 10 December 2018 – IFPMA, the global research-based biopharmaceutical industry association, is pleased to ...

Read More

2018-12-05 12:00:49

R&D biopharmaceutical industry revamp ethical code to apply as base line of industry behavior worldwide

New R&D biopharmaceutical industry Code of Practice comes into effect on 1 January 2019. Changes ...

Read More

2018-12-04 17:17:22

David A. Ricks Elected New President of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA)

David A. Ricks, Chairman and Chief Executive Officer, Eli Lilly and Company, takes over as ...

Read More

2018-11-16 06:30:08

Pharma industry launches call for coalition of countries to pilot new incentives for antibiotic R&D

16 November, Geneva – The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) draws attention ...

Read More

2018-11-13 09:35:59

The largest private sector coalition to provide sustainable solutions to curb antimicrobial resistance (AMR) has made strides in 2018 and calls for a coordinated and multi-pronged response from all stakeholders

The AMR Industry Alliance has made major strides in 2018 taking action across four different ...

Read More

2018-10-29 10:25:29

The R&D biopharmaceutical industry supports the Astana Declaration and renewed political commitment towards the importance of primary health care

26 October 2018, Astana – The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), the ...

Read More

Latest Statement

2019-05-27 16:21:25

IFPMA Statement at WHA72 agenda item 11.7 Access to medicines and vaccines

IFPMA, supported by ICBA, share the goal of WHO and its Members to ensure appropriate access to affordable and quality-assured ...

Read More

2019-05-25 16:45:55

IFPMA Statement at WHA72 agenda item 12.10 The public health implications of implementation of the Nagoya Protocol

26 October 2018, Astana – The International Federation of Pharmaceutical ...

Read More

2019-05-24 18:16:31

IFPMA Statement at WHA72 12.1 agenda item Pandemic Influenza Preparedness Framework for the sharing of influenza viruses and access to vaccines and other benefits

26 October 2018, Astana – The International Federation of Pharmaceutical ...

Read More

2019-05-22 11:57:20

IFPMA Statement at WHA72 agenda item 1.5 Universal Health Coverage

26 October 2018, Astana – The International Federation of Pharmaceutical ...

Read More

2019-04-01 14:41:22

IFPMA Statement at the 22nd WHO Expert Committee Meeting on the Selection and Use of Essential Medicines

26 October 2018, Astana – The International Federation of Pharmaceutical ...

Read More

2019-03-21 10:20:39

Statement on influenza vaccine supply in the 2019-20 Northern Hemisphere season

26 October 2018, Astana – The International Federation of Pharmaceutical ...

Read More

2019-02-06 10:17:10

EB 144 agenda item 5.5 Universal health coverage

26 October 2018, Astana – The International Federation of Pharmaceutical ...

Read More

mailto:s.kaenzig@ifpma.org +41 22 338 32 49
direct line
Twitter skaenzig

Sadia Kaenzig - Communications Manager

Sadia manages communications on issues including regulatory, intellectual property protection, trade and the economic footprint of the research-based pharmaceutical industry, research and development ecosystem and innovation, vaccines including influenza vaccines, and biotherapeutics.

mailto:m.depol@ifpma.org +41 22 338 32 20
direct line
Twitter @MorganePol

Morgane De Pol - Communications and Public Affairs

Morgane manages communications on issues including the research-based pharmaceutical industry’s commitment to achieving sustainable and inclusive development, advancing Universal Health Coverage, designing transformational partnerships to build healthier societies, boosting innovation for neglected tropical diseases, expanding access to high quality treatments for infectious and chronic diseases, fighting counterfeit medicines, and promoting resilient and efficient health systems.

A shared commitment to global health

Our Brouchure

2015 Edition

A shared commitment to global health

At IFPMA we advocate policies and practices that encourage the discovery of and access to life-saving and life-enhancing medicines and vaccines, for people everywhere.


Our Logo

Full colour EPS format

Our Logo

Full colour PNG format


FULL Name LOGO

Full colour EPS format


FULL Name LOGO

Full colour PNG format

Hot Topic

Pharmacovigilance: Do your bit, play your part!

Pharmacovigilance is one of the key steps to ensuring the safety of all our medicines, including biotherapeutics and vaccines. It encourages an ongoing cycle of communication between patients, health professionals, regulatory authorities, and our biopharma industry which is

Read More

Interview

IFPMA 2015 interview series 'Biodiversity, human health, and pharma'

A must-watch: Dr Manisha A. Desai, assistant general patent counsel at Eli Lilly and Company, gives her take on the importance of the Convention of Biodiversity and the Nagoya Protocol for the pharma industry. What's key is to

Read More

Our Blog

Latest Tweets

🎬 Missed our side-event at #WHA72? Catch the highlights of the discussion on #healthpartnerships, healthcare system… https://t.co/B4r1utE3ur
5 6
Collaboration efforts among our partners will not only help #vaccineswork, but also contribute to a healthier and m… https://t.co/svsUzcOVIG
“I’ve learnt how fragile progress in #immunisation can be […] eliminating a disease is not the finish line – we mus… https://t.co/Svtjld2Vuq
#Immunization saves lives. 💉👨‍👧‍👦 Check out our new series on #vaccineswork, where our experts discuss investing in… https://t.co/RMVitouCZd
1 1
New @CGDev report outlines solutions for eliminating inefficiencies in #procurement systems for LMICs:… https://t.co/7kOCqFXkpO